Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (R41/R42)-Clinical Trial Not Allowed | PA 18 709

Opportunity Information: Apply for PA 18 709

This funding opportunity, titled "Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (R41/R42) - Clinical Trial Not Allowed" (Funding Opportunity Number PA 18 709), is an NIH grant program aimed specifically at small businesses that can build new research-enabling tools for neuroscience and mental health science. It sits in the NIH small business grant mechanisms (R41/R42, which align with SBIR/STTR-style phased development), and it is administered under the National Institutes of Health with a focus aligned to the National Institute of Mental Health (NIMH). The central idea is not to fund clinical testing in humans, but to fund technology development that makes it easier for the broader research community to study and control a particularly important class of brain targets: G-protein coupled receptors (GPCRs).

The scientific focus is on brain-localized GPCRs and on the kinds of technologies that can reveal how these receptors work in real biological contexts, where their structure and function can change over time. GPCRs are major signaling proteins involved in neurotransmission and neuromodulation, and many psychiatric medications act on GPCRs either directly or indirectly. Because mental health conditions are often linked to altered signaling dynamics, receptor localization, receptor conformations, and circuit-level effects, NIMH is signaling interest in tools that do more than just measure whether a receptor is present. The program emphasizes technologies and approaches that help researchers understand and manipulate the dynamic structure and/or function of these receptors in the brain, meaning tools that can capture receptor states, signaling pathways, receptor interactions, trafficking, ligand bias, temporal changes, or context-specific activation in relevant neural systems.

A second major objective is the development of approaches that could enable identification of better chemical probes or candidate therapeutics for these receptors, specifically ligands that are selective and specific. The opportunity explicitly mentions the potential to identify novel agonists, antagonists, or allosteric modulators for GPCR subtypes. In practical terms, that points to platforms and assays that can discover, screen, or validate compounds with improved subtype selectivity, functional selectivity (biased agonism), or allosteric modulation, which is often a route to greater specificity and fewer side effects. The emphasis on "selective and specific" suggests the funder is looking for methods that reduce the common problem of off-target activity across the large GPCR family, especially when targets are closely related.

NIMH also makes clear that the program is open to technologies targeting both well-characterized receptor subtypes and understudied or orphan GPCRs. That matters because many GPCRs expressed in brain remain poorly understood, with unknown endogenous ligands or unclear roles in neural circuits. By explicitly welcoming orphan and understudied receptors, the announcement encourages small businesses to tackle higher-risk, potentially higher-reward targets, as long as the proposed technology or approach plausibly advances the ability to interrogate receptor biology relevant to mental health function or dysfunction. This can include enabling tools that de-risk discovery by providing better receptor expression systems, more physiologically relevant assay formats, better readouts of signaling, or structural and computational approaches that help connect receptor conformation to function.

From an applicant eligibility standpoint, the opportunity is limited to small businesses. Foreign institutions that are non-U.S. entities are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible to apply as components. However, the notice indicates that "foreign components," as defined under the NIH Grants Policy Statement, may be allowed in certain cases. In NIH terms, that generally means a U.S. small business could potentially include a limited, well-justified element of work performed outside the U.S. if it meets NIH policy requirements and is clearly necessary for the project, but the applicant organization itself must be an eligible U.S. small business and the core of the project is expected to be led and managed from the U.S.

Administratively, this is a discretionary grant program under the health funding activity category (CFDA 93.242). The original closing date listed in the source data is 2021-09-05, and the opportunity record was created on 2018-03-15. The source information provided does not specify an award ceiling or the expected number of awards, which typically means applicants would need to consult the full funding announcement and NIH budget guidelines for the relevant small business mechanism to understand allowable budgets, phase structure expectations, and project period limits.

Overall, the opportunity is best understood as a call for enabling technologies rather than a call for conducting clinical trials or delivering a near-term therapeutic. The funder is looking for tool-building and platform development that helps the field study GPCRs in the brain with greater precision and realism, and that can open up new paths to discovering or characterizing receptor modulators relevant to mental health. The common thread is practical impact on research capabilities: methods that allow clearer mechanistic insight into GPCR signaling in neural systems and that help bridge the gap between receptor biology and mental health-related function or dysfunction, without moving into clinical trial activity under this particular announcement.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (R41/R42)-Clinical Trial Not Allowed" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242.
• This funding opportunity was created on 2018-03-15.
• Applicants must submit their applications by 2021-09-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for PA 18 709

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: